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This investigation describes the prevalence of upper-body symptoms in a population-based 
sample of women with breast cancer (BC) and examines their relationships with upper-body 
function (UBF) and lymphoedema, as two clinically important sequelae. Australian women 
(n=287) with unilateral BC were assessed at three-monthly intervals, from six to 18 months 
post-surgery (PS). Participants reported the presence and intensity of upper-body symptoms 
on the treated side. Objective and self-reported UBF and lymphoedema (bioimpedance 
spectroscopy) were also assessed. Approximately 50% of women reported at least one 
moderate-to-extreme symptom at 6- and at 18-months PS. There was a significant 
relationship between symptoms and function (p<0.01), whereby perceived and objective 
function declined with increasing number of symptoms present. Those with lymphoedema 
were more likely to report multiple symptoms and presence of symptoms at baseline 
increased risk of lymphoedema (ORs>1.3, p=0.02). Although, presence of symptoms 
explained only 5.5% of the variation in the odds of lymphoedema. Upper-body symptoms are 
common and persistent following breast cancer and are associated with clinical ramifications, 
including reduced UBF and increased risk of developing lymphoedema. However, using the 
presence of symptoms as a diagnostic indicator of lymphoedema is limited. 
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Introduction 
The extent of arm morbidity, including the presence of upper-body symptoms, 
following treatment for breast cancer was a major driving force in the quest for identifying less 
invasive treatment strategies that could reduce morbidity without adversely influencing 
survival (1). There is now an established and growing literature base demonstrating that 
morbidity following treatment is reduced among those who undertake less invasive treatment 
options, such as sentinel node biopsy versus axillary dissection, breast-conserving surgery 
versus mastectomy, and/or radiation to the axilla only versus chest wall in addition to axilla (2-
7). However, it is difficult to distil from this literature how common the presence of symptoms 
are for the wider breast cancer community, because these studies typically deal with specific 
clinical cohorts, and for some, cancer stage may dictate more invasive treatment. Further, 
many assess only a subset of the known symptoms reported by women with breast cancer 
(e.g., weakness, stiffness and tingling are rarely assessed) and it is plausible that we’re yet to 
fully understand the full spectrum of possible symptoms women experience. 
 
Upper-body morbidity, as defined by presence of specific symptoms (such as pain 
and/or oedema), and dysfunction (as assessed by strength and/or flexibility), has been 
associated with restrictions in daily activities and reduced quality of life (8-11). This work 
provides direct evidence demonstrating the importance of managing symptoms with respect 
to optimising quality of life. However, the clinical consequences of upper-body symptoms on 
upper-body function (UBF) and lymphoedema are less understood. Of particular interest is 
whether presence of symptoms can be used to predict who will develop lymphoedema and/or 
whether specific symptoms can be used as diagnostic criteria. 
 
The purpose of this work therefore is to describe the presence of upper-body 
symptoms between six- and 18-months following breast cancer surgery in a prospective, 
longitudinal study involving a population-based sample. A major objective is to explore the 
relationships between upper-body symptoms, and UBF and lymphoedema. 
 
Materials and Methods 
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Patient group 
This work represents a planned component of the Pulling Through Study, which was 
designed to track the physical and psychosocial recovery of a cohort of Australian women 
between six- and 18-months following breast cancer (12). Eligibility criteria included a first 
diagnosis of invasive, unilateral breast cancer, age of 74 years or younger and place of 
residence within a 100 kilometre radius of Brisbane, Queensland.  A unilateral diagnosis 
allowed for the untreated side to serve as a ‘control’ for certain outcomes, such as 
lymphoedema, while the residence criterion facilitated logistics of collection of objective 
outcomes. Excluding women 75 years and older minimised the potential impact that other 
age-related co-morbidities may have on study findings. 
 
Following ethical approval, population-based sampling was undertaken through the 
Queensland Cancer Registry. It takes up to three months for patient records to arrive at the 
Registry, therefore recruitment procedures commenced at approximately four-months post-
surgery (PS). Registry recruitment processes dictate the need for doctor consent before 
potential participants can be approached and was obtained from doctors of 417 (out of 511) 
women. Participant consent was then received from 71% (n=294) of these women, with 
seven withdrawing consent or unable to be contacted before baseline assessment. Hence, 
287 women participated in baseline measures (six-months PS). Of these, the majority (75%) 
participated in all components (clinical and questionnaire assessment) of data collection, 
while the remainder participated on a ‘questionnaire-only’ basis (that is, objective 
lymphoedema data are not available for these women). 
 
Data collection 
Participation in the study involved five data collection sessions, commencing at six-
months PS and every three months thereafter. The self-administered questionnaire was used 
to collect information on a range of patient, treatment and behavioural characteristics, 
including age, income, number and ages of children, body mass index (BMI), place of 
residence, marital status, side of dominance, physical activity levels, and type of surgery and 
adjuvant therapy undertaken. Disease characteristics were collected from medical records at 
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the Cancer Registry. Our clinical assessment protocol (described elsewhere [8]) was used to 
objectively quantify aspects of UBF and evidence of lymphoedema. 
 
Upper-body symptoms and self-reported upper-body function 
Information pertaining to presence and severity of upper-body symptoms was 
assessed using the Functional Assessment of Cancer Therapy-Breast (FACTB+4) 
questionnaire (13), specifically the arm subscale. The FACTB+4 arm subscale asks women to 
rate the severity of pain, range of movement (ROM), numbness, stiffness and swelling on the 
treated side during the past seven days, by reporting how ‘true’ on a 5-point Likert-like scale 
of ‘not at all’ through to ‘very much’, are statements regarding each symptom: for example. 
‘one or both of my arms are swollen or tender’, ‘I have poor range of arm movement on this 
[treated] side’. The score from each of the these items is summed to form the FACTB+4 arm 
subscale (14), with final scores ranging between 0 to 20 (higher scores reflect lower number 
and/or severity of arm symptoms). In addition to calculating the arm subscale, each item was 
assessed separately to determine the proportion of women who reported ‘somewhat’ to ‘very 
much’ for individual symptoms, as this was a priori defined as the measure by which to 
identify clinically relevant symptoms. 
 
The Disability of the Arm, Shoulder and Hand (DASH) questionnaire was 
administered as a measure of self-reported UBF. The DASH (15) comprises 30 items and 
collects information about the level of difficulty experienced when performing specific tasks, 
the extent to which any upper-body problem interferes with normal activities, and the severity 
of specific upper-body symptoms (pain, tingling, weakness and stiffness). Final scores range 
from 0 to 100, where 0 reflects no disability (good function) and 100 reflects extensive 
disability (poor function). 
 
In addition to using the DASH to assess UBF, the tingling and weakness symptom 
items were considered separately to calculate the proportion of women reporting these 
symptoms as moderate to extreme (a priori defined as clinically important). These two 
symptoms are not captured by the FACTB+4 arm subscale. 
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Objective measures of upper-body function and lymphoedema 
Clinical assessments of UBF were conducted for strength and endurance using an 
incremental exercise protocol, with each stage lasting one minute in duration and increments 
made by increasing speed of movement and weight held (0.5kg increments, with the first one-
minute stage commencing with no weight held). The movement combined a traditional 
‘upright row’ and ‘shoulder press’, but the specific ROM was individualised for each participant 
and each arm. To advance levels, the participant must have maintained correct form, ROM 
and speed for the entire one-minute stage. Weight (kilograms) held during the last 
successfully completed stage, assessed separately for each arm, was recorded. More details 
including comparison of this technique with assessment of strength and endurance using an 
isokinetic dynamometer are reported elsewhere (16). 
 
Lymphoedema status was evaluated objectively using bioimpedance spectroscopy 
(BIS) (12). The impedance of the extracellular fluid for each limb was assessed using a SEAC 
SFB7 monitor (SEAC Australia, Impedimed), and the ratio of impedance values, comparing 
the treated and untreated sides, was then calculated. A participant was classified as having 
lymphoedema when the impedance ratio was more than three standard deviations above 
normative data, taking into account side of dominance (17, 18). 
 
Statistical methods 
Distributions of the FACTB+4 arm subscale scores were approximately Normal, 
hence means and standard deviations were used to summarise data at each time point. A 
change in three units of the arm subscale score was a priori defined as clinically important [1]. 
Percentages were used to describe the prevalence of upper-body symptoms at each testing 
phase. Unadjusted relationships between the FACTB+4 arm subscale and objective and self-
reported UBF were assessed using Pearson correlations, while analysis of variance was used 
to determine the statistical significance of the unadjusted, cross-sectional relationships 
between upper-body symptoms and UBF at six months. The latter included an interaction 
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term to consider the effect of lymphoedema status on the overall relationship. Tukey’s tests 
were used for post-hoc pairwise comparisons. 
 
The independent predictive relationships of upper-body symptoms and UBF at six-
months PS with development of lymphoedema between nine- and 18-months PS were 
explored using logistic regression. Symptoms and function were separately added to a model 
that included all those characteristics found to be statistically or clinically predictive of 
lymphoedema in prior work (12). 
 
Results 
 Study participants were, on average, aged 54 years (standard deviation, SD 10 years); 
approximately 74% were diagnosed with infiltrating ductal carcinoma; 74% received complete 
local excision; and 87% had one or more lymph nodes dissected, with a median of 12 (range: 
1-47) nodes examined and 0 (range: 0-39) positive nodes. Adjuvant therapy was common, as 
approximately 70%, 40% and 60% of women received radiation therapy, chemotherapy and 
hormone therapy, respectively. The demographic and clinical characteristics of the sample 
were generally representative of the target sample (n=511) and representative of the wider 
breast cancer community, with more detailed results presented elsewhere (12). 
   
Presence of upper-body symptoms 
Scores derived from the FACTB+4 arm subscale, which included items relating to 
pain, ROM, numbness, swelling and stiffness, were stable over time (mean±SD = 16.2±3.8 at 
six-months PS; 17.0±3.6 at 18-months PS; Table 1). Those with lymphoedema had lower arm 
subscale scores at each phase when compared to those without lymphoedema; however, the 
differences were neither statistically, nor clinically, significant (data not shown). 
 
When considering results from individual items, taken from the DASH and FACTB+4, 
almost 50% of women reported at least one moderate to extreme upper-body symptom at six-
months PS (Table 1) and 51% of these women continued to report symptoms at 18-months 
PS. While at all testing phases, numbness and swelling were the most common symptoms 
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(reported by 19-29% and 13-23%, respectively), confidence intervals for the majority of 
symptoms overlapped. Of those reporting symptoms, between 57-82% reported these 
symptoms as moderate, with the remainder reporting symptoms as severe or extreme. In 
general, the proportion of women reporting symptoms declined over time, and these results 
were statistically significant for numbness and swelling (p<0.05) but only clinical relevant for 
numbness. At 18-months PS, 33% of women reported one or more symptoms. 
 
With the exception of stiffness, those with lymphoedema were between 1.6-3.4 times 
more likely to report specific moderate to extreme symptoms at six-months PS (Figure 1) and 
the differences in proportions were statistically significant (p<0.05) for tingling (3.4-fold 
increase) and weakness (2.3-fold increase). By 18-months PS, the differences in proportions 
reporting weakness, stiffness and poor ROM between those with and without lymphoedema 
were minimal (Figure 2). Those with lymphoedema were, however, more likely to report 
tingling, swelling (p<0.05) and numbness. The proportions of women reporting the presence 
of any one symptom, irrespective of lymphoedema status, were the same at six-months PS, 
but multiple symptoms (2+) were 1.7 times more common among those with lymphoedema 
(p<0.05) (data not shown). By 18-months PS, having lymphoedema doubled the likelihood of 
reporting one or more symptoms (p<0.05). 
 
Relationships between upper-body symptoms and upper-body function 
Higher FACTB+4 arm subscale scores (indicating reduced number and/or intensity of 
arm symptoms) had a modest association with better objectively-measured UBF (depending 
on lymphoedema status r=0.2-0.3, p<0.01) and was moderately associated with higher 
perceived function (r=-0.6, p<0.01; lower DASH scores = better function). The presence of 
symptoms (0, 1, 2 or 3+ symptoms) was inversely associated with UBF (Table 2). Specifically, 
at six-months PS, having multiple symptoms was associated with lower objective and 
perceived UBF (p<0.01). These associations remained the same irrespective of 
lymphoedema status (p=0.67 for objective UBF and p=0.72 for subjective UBF). 
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Relationship between incidence of lymphoedema and upper-body symptoms and 
upper-body function at 6 months PS  
Table 3 presents the unadjusted and adjusted predictive relationships between upper-
body symptoms and UBF at six-months PS and incidence of lymphoedema between 9 and 18 
months PS, as assessed separately in 4 different models (one model each for upper-body 
symptoms, FACTB+4 arm subscale, objective UBF and self-report UBF). Odds of 
lymphoedema increased two-fold, with the presence of one or more symptoms at six-months 
PS (p<0.05). For every one unit increase in the arm subscale score (indicating fewer and/or 
less severe symptoms), every one unit increase in objective UBF and every one unit 
decrease in self-report UBF (whereby lower scores indicate improved function) there was a 
6%, 20% and 1% reduction in the odds of lymphoedema, respectively, although these 
associations were not supported statistically. 
 
The inclusion of upper-body symptoms, arm subscale score, objective UBF or self-
reported UBF into a model that takes into account other important predictive personal, 
treatment and behavioural characteristics (which together explain 25.5% of the total 
variance), contributed an additional 5.5%, 1.5%, 0% and 9.5% of the total variance explained, 
respectively. Both multiple symptoms (p=0.02) and the FACTB+4 arm subscale (p=0.09) at 
six-months PS were independently associated with lymphoedema status at nine- to 18-
months PS. Similarly, poorer self-reported UBF at baseline was associated with greater odds 
of later having lymphoedema (p=0.04), whereas objective UBF was not. 
 
Discussion 
Upper-body morbidity is common following treatment for breast cancer despite 
advances in treatment methods that have led to less invasive surgical techniques, such as 
sentinel node biopsy, and more refined, targeted radiation methods. One in two women report 
moderate to extreme pain, tingling, weakness, stiffness, poor ROM, swelling and/or 
numbness at six-months PS, and 51% of these women report at least one of these arm 
complaints 12-months later. Further, the majority of those reporting moderate-extreme 
symptoms (56-68% across time points) report the presence of multiple symptoms. 
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Experiencing upper-body symptoms is associated with both objectively measured and self-
reported UBF. Additionally, the presence of multiple symptoms six months following breast 
cancer surgery is associated with subsequent development of lymphoedema, although no 
particular symptom is diagnostic. 
 
By using the percentage of women reporting specific symptoms, symptoms could be 
ranked from the most common through to the least common, for all women, as well as for 
those with and without lymphoedema. When this is done, numbness and swelling are the 
most common symptoms and poor ROM is the least common, irrespective of lymphoedema 
status and time of measurement. While others report poor ROM (11), pain (9) or tightness 
(19) as being among the most common, the number and type of symptoms assessed differed 
between studies. Further, it is important to highlight that confidence intervals around the 
percentages reported in our work are wide, and it is likely that this is the case in other studies, 
although typically not reported. Consequently, it seems more appropriate to highlight that 
symptoms are common and varied, rather than focusing on which symptom is the most or 
least common and whether the presence of any one specific symptom is an indicator of 
lymphoedema status. 
 
Using instruments such as the FACTB+4 arm subscale or the BR 23 subscale of the 
European Organisation for Research and Treatment of Cancer quality of life questionnaire 
(20), which fail to capture the broad spectrum of possible symptoms, may also fail to capture 
the full extent of morbidity caused by upper-body symptoms following breast cancer and how 
morbidity changes over time. In this study, despite there being fewer women reporting 
moderate to extreme symptoms at 18-months as compared to six-months PS, there was no 
change observed in the arm subscale score over this time frame. Also, there was no 
difference in mean arm subscale scores (and the variance around the mean) for those with 
lymphoedema compared to those without lymphoedema, but by looking at individual 




We also explored the unadjusted relationship between upper-body symptoms and 
UBF and found an inverse, linear relationship with self-reported function. Upper-body 
symptoms were also associated with objective UBF, but results suggested that multiple 
symptoms, as opposed to any one symptom, were required before declines in objective UBF 
were observed. Although findings require further investigation, it seems plausible that 
measurement of symptoms in the clinical setting could be used to educate women that the 
presence of symptoms may be more likely to influence perceived function than actual function 
and to help identify women who may benefit from physical/exercise therapy to optimise 
objective UBF. 
 
The results from this work raise questions as to whether the presence of upper-body 
symptoms or reduced UBF can be used as diagnostic criteria for lymphoedema, as currently 
occurs in clinical practice. While this work demonstrates that the presence of symptoms 
and/or reduced perceived UBF are risk factors for developing lymphoedema, these 
characteristics in addition to the 11 other clinically and/or statistically important personal, 
treatment and behavioural characteristics explain no more than 35% of the variation between 
those who do and do not develop lymphoedema. Therefore, while presence of symptoms 
and/or reduced UBF are of clinical relevance, caution should be applied when using this 
information in the diagnosis of lymphoedema. Lymphoedema is considered the most feared 
breast cancer complication and its treatment is costly and time-consuming (21), highlighting 
the importance of minimising misdiagnosis. 
 
This work could be criticised for presenting results of individual items taken from a 
psychometric questionnaire and for including ‘swelling’ as a symptom when lymphoedema 
was objectively assessed. It is important to note that participants responded to the symptom 
questions by completing the psychometric questionnaires (FACTB+4 and DASH) in their 
validated format. We then described the response from each item separately, and in doing so, 
have been able to extract more information about reported symptoms than otherwise would 
have been available from the subscale score alone. With respect to including swelling as one 
of the symptoms assessed, all analyses considering symptoms grouped (as 0, 1, 2, 3+) were 
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replicated with swelling removed and results remained unchanged (data not shown). This was 
anticipated, as previous work (22) demonstrated that approximately 40% of those with 
lymphoedema (according to BIS) do not report swelling and 40% of those without 
lymphoedema (according to BIS) report swelling. 
 
Conclusion 
This was a longitudinal study, using a population-based, representative sample of 
women with breast cancer, with results representing current estimates of upper-body 
morbidity between six- and 18-months PS. It is evident that upper-body morbidity following 
breast cancer treatment is common and persists into longer-term survivorship. Further, the 
results demonstrate that presence of symptoms has clinical ramifications with respect to UBF 
and development of lymphoedema. Consequently, these results provide support for the 
assessment and management of symptoms to be integrated within standard care of women 
with breast cancer, with a focus on minimising burden and optimising function. However, 
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Table 1 Mean arm subscale scores and percentages of women experiencing specific upper-body symptoms at six-, nine-, 12-, 15- and 18-months 
post-surgerya 
 Months post-surgery 
 6 9 12 15 18 
 n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
           
FACTB+4 arm subscale 285 16.2 (3.8) 277 16.5 (3.8) 277 16.8 (3.5) 270 17.0* (3.3) 271 17.0* (3.6) 
      
Upper-body symptomsb nc % nc % nc % nc % nc % 
       
Tingling 40 13.7 38 14.1 28 10.5 30 11.4 31 12.0 
Weakness 54 18.6 50 17.9 41 14.9 38 14.2 37 13.7 
Pain 41 14.3 43 15.6 34 12.3 33 12.3 28 10.4 
Poor ROM 29 10.1 31 11.2 27   9.8 25   9.2 28 10.0 
Numbness 86 29.2 68 24.1 62 22.1d 55 19.5d 52 18.6d 
Stiffness 42 13.9 37 12.9 30 10.4 25   9.1 30 10.8 
Swelling 67 22.8 55 20.0 52 19.0 37 13.5d 40 15.1d 
Number of symptoms      
0 148 52.8 163 58.6d 164 59.2d 173 63.7d 181 66.9d 
1 59 20.1 37 13.2 50 18.0 40 15.2 36 13.0 
2 25 8.6 31 11.3 23   8.4 21   7.7 19   6.9 
3+ 55 18.5 48 17.0 40 14.3 37 13.4 36 13.1 
 
a Results presented have been appropriately weighted (< 50 years:1.0; > 50 years:1.3) for oversampling of younger women. 
b Symptoms: tingling and weakness as “moderate to extreme” (taken from DASH questionnaire); pain, poor range of movement (ROM), numbness, stiffness 
and swelling defined as “somewhat to very much” (items comprise the FACTB+4 arm subscale range 0 to 20).  
c Number of women with symptoms at each time point. 
d Statistically significant difference (p<0.05) from 6 months post-surgery, as determined by post-hoc Tukey’s  post-hoc test when the overall p-value was 
p<0.05; for number of symptoms, statistically significant difference (p<0.05) relates to women reporting 1+ symptoms compared to 0 symptoms. 
Abbreviations: ROM, Range of movement; FACTB+4, Functional Assessment of Cancer Therapy, Breast questionnaire; SD, standard deviation. 
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Table 2 Relationships between concurrent upper-body symptoms and upper-body function at six-months following breast cancer surgerya 
 Upper-body symptomsb at six-months post-surgery 
Mean (95% CI) 
 n 0 1 month 2 months More than 3months Overall 
p-value 
 
Upper-body function   
Objective (UBSE; kg) 212 0.8 (0.7, 0.9) 0.9 (0.8, 1.1) 0.6 (0.4, 0.8) 0.5 (0.4, 0.6)c <0.01 
Self-reported (DASH) 258 7.1 (6.0, 8.2) 11.4 (9.0, 13.8)c 22.4 (17.5, 27.3)c 31.9 (27.9, 35.9)c <0.01 
       
 
a Results presented have been appropriately weighted (< 50 years:1.0; > 50 years:1.3) for over sampling of younger women. 
b Symptoms: tingling and weakness as “moderate to extreme” (taken from DASH questionnaire); pain, poor range, numbness, stiffness and swelling defined 
as “somewhat to very much” (taken from the FACTB+4 questionnaire). 
c Statistically significant difference p<0.05 when compared with score for 0 symptoms, as determined by Tukey’s post-hoc test. 
Abbreviations: UBSE, upper-body strength and endurance; DASH, Disability of the Arm, Shoulder and Hand questionnaire (0-100 scale, lower score = better 
function); CI, Confidence Interval. 
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Table 3 Relationships between upper-body symptoms and upper-body function at baseline and lymphoedema incidence (n=55) between 9 and 18 months 
post-surgerya 
  Odds of Lymphoedema 9 to 18 months post-surgery 
  Crude Results Adjusted Resultsb 
 n OR   (95% CI) p-value      OR  (95% CI) p-value R2 
 
Symptomsc at 6 months post-surgery 
 









1.00    ref 
1.92   (0.90, 4.08) 
1.54   (0.55, 4.31) 
2.82   (1.33, 5.99) 
0.05 1.0      ref 
2.41   (1.03, 5.65) 
1.37   (0.39, 4.87) 
4.07   (1.53, 10.80) 
0.02 0.31 
 
FACTB+4 arm subscale  
181 
 
0.94  (0.88, 1.01) 
0.08  
0.92   (0.84, 1.01) 
0.09 0.27 
 
Objective UBF (UBSE)  
177 
 
0.83  (0.44, 1.56) 
0.56  








1.01  (0.99, 1.03) 
0.38  
1.03   (1.00, 1.06) 
0.04 0.35 
 
a Results presented have been appropriately weighted (< 50 years, 1.0; ≥ 50 years, 1.3) for oversampling of younger women.  
b Models adjusted for baseline age, treatment on dominant side, income, marital status, children, BMI, type of surgery, extent of lymph node dissection, 
radiation, chemotherapy and physical activity. 
c Symptoms: tingling and weakness as “moderate to extreme” (taken from DASH questionnaire); pain, poor range of movement (ROM), numbness, stiffness 
and swelling defined as “somewhat to very much” (items comprise the FACTB+4 arm subscale range 0 to 20). 
Abbreviations: FACTB+4, Functional Assessment of Cancer Therapy Breast questionnaire, arm subscale; UBSE, upper body strength and endurance; DASH, 
Disability of the Arm, Shoulder and Hand questionnaire (0-100 scale, lower score = better function); OR, Odds ratio; UBF, Upper-body function. 
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Figure 1 Proportions (95% CI) of women with (Yes) or without (No) lymphoedema, reporting 
moderate to extreme upper-body symptoms at 6 months post-surgerya  
 
Figure 2 Proportions (95% CI) of women ever (Yes) or never (No) having lymphoedema, 
reporting moderate to extreme upper-body symptoms at 18 months post-surgerya 
 
